Special Issue "Locoregional Treatment and Gene Targeted Therapies for Cancer Metastasis"

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: 30 April 2019

Special Issue Editor

Guest Editor
Prof. Dr. Katrien Remaut

Lab General Biochemistry and Physical Pharmacy, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium
Website | E-Mail
Interests: peritoneal carcinomatosis, advanced microscopy methods, nucleic acid delivery, non-viral gene delivery, stability in biological fluids, intracellular trafficking

Special Issue Information

Dear colleagues,

Cancer, including breast cancer, skin cancer, lung cancer, colon cancer and prostate cancer still affects millions of people every year. Cancer treatment often includes non-specific interventions such as surgery, chemotherapy and/or radiation therapy. Targeted therapies, however, specifically interfere with the biology of the cancer cells, to prevent the growth and formation of metastasis. Biological therapies such as immunotherapy, antibodies, gene therapy and cell-based therapy are also rapidly progressing. Furthermore, smart delivery strategies such as tumor-environment responsive materials, controlled-release formulations or the application of local triggers (light, heat, ultrasound, etc.) can locally boost the therapeutic potential.

In this Special Issue, we will publish reviews and original research that provide new insights into gene targeted therapies for cancer metastasis and how locoregional treatment can advance the therapeutic outcomes. Novel insights into the delivery aspects of gene targeted therapies will be particularly welcomed.

Prof. Dr. Katrien Remaut
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • nucleic acids in cancer treatment (siRNA, mRNA, pDNA, …)
  • antibodies in cancer treatment
  • immunotherapy
  • cancer vaccines
  • cancer gene therapy
  • cell based therapy
  • mesenchymal to epithelial cell transition
  • tumor environment responsive materials
  • controlled release formulations
  • locoregional triggered drug delivery
  • delivery barriers to targeted cancer therapies

Published Papers (1 paper)

View options order results:
result details:
Displaying articles 1-1
Export citation of selected articles as:


Open AccessArticle Novel Ran-RCC1 Inhibitory Peptide-Loaded Nanoparticles Have Anti-Cancer Efficacy In Vitro and In Vivo
Cancers 2019, 11(2), 222; https://doi.org/10.3390/cancers11020222
Received: 29 December 2018 / Revised: 31 January 2019 / Accepted: 11 February 2019 / Published: 14 February 2019
PDF Full-text (6886 KB) | HTML Full-text | XML Full-text | Supplementary Files
The delivery of anticancer agents to their subcellular sites of action is a significant challenge for effective cancer therapy. Peptides, which are integral to several oncogenic pathways, have significant potential to be utilised as cancer therapeutics due to their selectivity, high potency and [...] Read more.
The delivery of anticancer agents to their subcellular sites of action is a significant challenge for effective cancer therapy. Peptides, which are integral to several oncogenic pathways, have significant potential to be utilised as cancer therapeutics due to their selectivity, high potency and lack of normal cell toxicity. Novel Ras protein-Regulator of chromosome condensation 1 (Ran-RCC1) inhibitory peptides designed to interact with Ran, a novel therapeutic target in breast cancer, were delivered by entrapment into polyethylene glycol-poly (lactic-co-glycolic acid) PEG-PLGA polymeric nanoparticles (NPs). A modified double emulsion solvent evaporation technique was used to optimise the physicochemical properties of these peptide-loaded biodegradable NPs. The anti-cancer activity of peptide-loaded NPs was studied in vitro using Ran-expressing metastatic breast (MDA-MB-231) and lung cancer (A549) cell lines, and in vivo using Solid Ehrlich Carcinoma-bearing mice. The anti-metastatic activity of peptide-loaded NPs was investigated using migration, invasion and colony formation assays in vitro. A PEG-PLGA-nanoparticle encapsulating N-terminal peptide showed a pronounced antitumor and anti-metastatic action in lung and breast cancer cells in vitro and caused a significant reduction of tumor volume and associated tumor growth inhibition of breast cancer model in vivo. These findings suggest that the novel inhibitory peptides encapsulated into PEGylated PLGA NPs are delivered effectively to interact and deactivate Ran. This novel Ran-targeting peptide construct shows significant potential for therapy of breast cancer and other cancers mediated by Ran overexpression. Full article

Figure 1

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top